Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Platelet-rich plasma (PRP) is a blood-derived fraction containing high level of platelets, a high concentration of leukocytes and growth factors. PRP therapy has been growing as a viable treatment alternative for several clinical applications and has a potential benefit for use in wound healing. Nowadays, platelet rich plasma is used in stimulating wound healing in skin and soft tissue ulcerations, accelerating wound healing in diabetic patients and facilitating bone proliferation in orthopaedic and trauma surgery. It has also applications in maxillofacial surgery, spinal surgery, plastic and aesthetic surgery, heart surgery and burns.
The global plasma therapy market is witnessing sustainable growth owing to rising incidences of sports injuries and advancements in the applications of plasma therapy. Moreover, the overall market is also being propelled by increase in the number of androgenic alopecia patients worldwide. The market is further boosted by the increased use of platelet-rich plasma in various therapeutic areas. Increase in the number of patients suffering from orthopaedic disorders and androgenic alopecia would further provide significant growth opportunities to this market in the future. However, the global plasma therapy market is hindered by lack of reimbursement policies and varying prices of plasma therapy.
The report analyses the global plasma therapy market based on type, source, application, end user and geography.
Based on type, the market is segmented into pure PRP, leucocyte-rich PRP, pure platelet-rich fibrin (PRF) and leukocyte-rich fibrin (L-PRF). Platelet-rich fibrin (PRF) or leucocyte and platelet-rich fibrin (L-PRF) is a second-generation PRP where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue and is used as a tissue-engineering scaffold for endodontics.
Based on source, this market is categorized into autologous and allogenic. Autologous Conditioned Plasma or ACP is plasma that is rich in platelets. ACP is used in the healing process of a patient and ensures that a patient is sufficiently supplied with his/ her own blood, blood that has been furthered treated to boost the healing process.
Plasma therapy market has applications in orthopaedics, dermatology, dental, cardiac muscle injury, nerve injury and others. The orthopaedics application includes arthritis, chronic tendinitis and bone repair & regeneration, whereas, the dermatology segment consists of androgenic alopecia and plastic surgery. Platelets play a central role in tissue regeneration. They function in hemostasis, construction of new connective tissue, and revascularization.
Various end users of this market are hospitals & clinics and research institutions. Plasma therapy provides a means of biological stimulation for tissue healing. It has the potential to be a powerful tool in the management of sports injuries, and as such, its popularity is on the rise.
By geography, the global plasma therapy market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world regions which includes Latin America, and Middle East & Africa. North America accounted for the largest market share in 2018, followed by Europe and APAC. In addition to this, APAC is projected to grow at a fastest CAGR, owing to increasing demand for plasma therapy in therapeutic conditions. Countries such as China and Japan are witnessing substantial growth in the plasma therapy market. Increase in aging population and rise in the number of orthopaedic disorders are likely to boost the market in the future.
The leading market players of the global plasma therapy market are Medtronic PLC, Integra Lifesciences Holdings Corporation, B. Braun Melsungen, Spiegelberg GmbH & Co. Kg, SOPHYSA (TKB Group), Natus Medical Incorporated, Dispomedica GmbH, Deltasurgical, Argi Grup, Moller Medical GmbH and Wellong Instruments Co., Ltd.
The global plasma therapy market is segmented based on type, source, application, end user and geography. Based on type, the market is segmented into pure PRP, leucocyte-rich PRP, pure platelet-rich fibrin (PRF) and leukocyte-rich fibrin (L-PRF). Platelet-rich fibrin (PRF) or leucocyte and platelet-rich fibrin (L-PRF) is a second-generation PRP where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue and is used as a tissue-engineering scaffold for endodontics.
Based on source, this market is categorized into autologous and allogenic. Autologous Conditioned Plasma or ACP is plasma that is rich in platelets. Plasma therapy market has applications in orthopaedics, dermatology, dental, cardiac muscle injury, nerve injury and others. The orthopaedics application includes arthritis, chronic tendinitis and bone repair & regeneration, whereas, the dermatology segment consists of androgenic alopecia and plastic surgery.
Various end users of this market are hospitals & clinics and research institutions. Plasma therapy provides a means of biological stimulation for tissue healing. It has the potential to be a powerful tool in the management of sports injuries, and as such, its popularity is on the rise.
By geography, the global plasma therapy market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world regions which includes Latin America, and Middle East & Africa. North America accounted for the largest market share in 2018, followed by Europe and APAC. In addition to this, APAC is projected to grow at a fastest CAGR, owing to increasing demand for plasma therapy in therapeutic conditions.
Why to buy this report:
